No abstract

Coronavirus is a new pandemic disease that began in Wuhan, China, and has since spread over the globe. The number of COVID-19 cases reported daily in Iraq has slowly increased. This study aims to investigate the effect of Covid-19 on the normal range of White Blood Cells (WBC), D-Dimer, and Lactate Dehydrogenase (LDH). This study looked at 65 patients who had tested positive for SARS-CoV-2 using polymerase chain reaction analysis. Patients with mild symptoms and a normal CT scan for the chest were separated into three groups: those with mild symptoms and a normal CT scan for the chest, those with intermediate disease presenting with fever and cough, other respiratory symptoms, and those with severe disease. At the time of the study, all patients' data were collected from Al-Diwaniyah Teaching hospital admission for parameters of White blood cell count, lactate dehydrogenase (LDH) levels, and D-Dimer levels, from December 27, 2020, to April 1, 2021. The WBC count, D-Dimer, and LDH in the patients with COVID-19 were higher than that of the control group (8.15 X109/L versus 390 ng/ml and 593 U/L), respectively, and the difference was highly significant (p < 0.001). There was no significant difference in WBC count and LDH among patients according to the severity (p > 0.05). A larger leukocyte count, D-Dimer, and LDH increased the risk of death. These signs can reliably predict a patient's prognosis while in the hospital. Our study's best lab marker was LDH.

Preeclampsia (PE) is a serious illness that can harm both mothers and unborn children and may even be fatal. It contributes significantly to maternal fatalities in underdeveloped countries. PE, which affects 2%–3% of women who are pregnant after 20 weeks of pregnancy, is marked by proteinuria and hypertension. PE is a significant condition that plays a significant role in maternal fatalities in underdeveloped countries and is a significant cause of death for both mothers and newborns. Each year, around 60,000 maternal fatalities occur in the world. Serum interleukin-6 (IL-6) was measured in pregnant women during the first trimester and second trimesters. IL-6 was necessary to establish serum biomarkers that can accurately predict the onset of preeclampsia. In a prospective cohort study that was conducted in the Obstetrics and Gynecology Department and Antenatal Care Unit at Maternity and Pediatrics Teaching Hospital in AL-Diwaniyah – Iraq, 160 pregnant patients between the years of 20 and 40 who were normotensive and had gestational ages of 10 to 13 weeks were included in this research between August 2021 and May 2022. Bioassays for IL-6 were conducted after blood samples were obtained. At the end of the study, it was confirmed that for women with pre-eclampsia (n = 33, 22.0%) and those women with no pre-eclampsia (n = 117, 78.0 %), there was no significant difference in the level between the preeclampsia and no preeclampsia group (p > 0.05).